+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global & USA Cancer Biomarker Market to 2018 (Identification, Technologies, Market Analysis, Competitor Profiles, Companion Diagnostic Co-Development, Business Strategies, Industry Trends and Pipeline Analysis)

  • ID: 2822261
  • Report
  • May 2014
  • Region: Global, United States
  • 232 Pages
  • Kelly Scientific Publications
1 of 4

FEATURED COMPANIES

  • 23andMe
  • Astex Pharmaceuticals
  • Celldex Therapeutics
  • Foundation Medicine
  • Illumina
  • OriGene Technologies
  • MORE
“GLOBAL & USA CANCER BIOMARKER MARKET to 2018 (Identification, Technologies, Market Analysis, Competitor Profiles, Companion Diagnostic Co-development, Business Strategies, Industry Trends, and Pipeline Analysis)” is a comprehensive report on the cancer biomarker industry and its impact on the health system. This report tackles the growing market interest in oncogenic biomarkers, personalized medicine, companion diagnostics and the associated market environment.

This is a comprehensive account of the market size, segmentation, key players, SWOT analysis, influential technologies, and business and economic environments. The report is supported by 280 tables & figures over 232 pages. The personalized medicine (global) market is presented as follows:

- By Company (e.g., 23andMe, AFFYMETRIX, ATOSSA GENETICS, NODALITY, deCode /Amgen, CELERA, MYRIAD, FOUNDATION MEDICINE, GENOMIC HEALTH)
- By Geography (Global, US)
- By Sub-market (Global Biomarker Market, Cancer Biomarker Market, Global Cancer Profiling Technology Market )

A wealth of financial data & business strategy information is provided including:

- Up-to-date company financials, sales & revenue figures
- Revenue and market forecasts up to 2018
- Business model strategies for diagnostic, pharmaceutical and biotechnology companies
- Therapeutics and Companion Diagnostics (e.g., BRAC Analysis, Oncotype Dx , KRAS Mutations)
- Comprehensive account of company product financials, portfolios & kits

SWOT, Economic & Regulatory Environment specifics include:

- Key strengths, weaknesses and threats influencing leading player position within the market
- Technologies driving the market (e.g., New-Generation Sequencing Technologies, Ultra-High Throughput Sequencing)
- Top fastest growing market segments and emerging opportunities
- Top pharmaceutical companies within the cancer biomarker market
- Comprehensive product portfolios, R&D activity and pipeline therapeutics
- M&A activity and future strategies of top companies
- Approved biomarker companion diagnostic tests
- High demand and Unmet Need Enhances the Global Biomarker Market
- FDA Support Increases Biomarker Development
- More Streamlined Clinical Trials
- Significant Growth of High-Impact Oncogenic Biomarker Research
- Advancements in Discovery Technologies
- Challenges of the Oncogenic Biomarker Market
- Variability of Biomarkers within Different Cancer Subtypes
- Integration of Genomics and Biomarker Diagnostics into the Healthcare System
- Ethical Considerations

This report highlights a number of significant Indian pharmacos and gives details of their operations, products, financials and business strategy.

- 23andMe
- Affymetrix
- Ambry Genetics
- Astex Pharmaceuticals
- Atossa Genetics
- BioMerieux
- CuraGen
- Celera Corporation (Quest Diagnostics)
- Celldex Therapeutics
- deCode Genetics (Amgen)
- Foundation Medicine
- Illumina
- Genelex
- Genomic Health
- Myriad
- Nodality
- OriGene Technologies
- Randox
- Qiagen
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • 23andMe
  • Astex Pharmaceuticals
  • Celldex Therapeutics
  • Foundation Medicine
  • Illumina
  • OriGene Technologies
  • MORE
1.0 Executive Summary

1.1 Objectives of Report

1.2 Data Sources and Methodology

1.3 Key Findings and Observations

1.3.1 What Makes Cancer Biomarkers so Important for the Healthcare Industry?

1.3.2 What Technologies are Used to Identify Novel Biomarkers?

1.3.3 Increase in Cancer Prevalence is Propelling the Oncogenic Biomarker Market

1.3.4 Global and US Economic Impact of Cancer

1.3.5 How Cancer Biomarkers are Revolutionizing Cancer Treatment

1.3.6 What are the most Significant and Strategic Cancer Biomarkers?

1.3.7 Global Biomarker Test Market Analysis

1.3.8 Global Cancer Biomarker Market Analysis

1.3.9 Oncology Biomarker Market Main Industry Players

1.3.10 Drivers, Restraints, Opportunities and Challenges of the Cancer Biomarker Market

2.0 Global Burden of Cancer

2.1 Global Cancer Statistics

2.2 Lung Cancer Globally

2.3 Lung Cancer Mutation Analysis

2.4 Colorectal (Bowel) Cancer Globally

2.5 Prostate Cancer Globally

2.6 Breast Cancer Globally

2.7 Global Economic Impact of Cancer

2.8 Cancer in the USA

2.9 Breast Cancer in the US

2.10 Lung Cancer in the US

2.11 Colorectal Cancer in the US

2.12 Prostate Cancer in the US

2.13 Skin Cancer in the US

3.0 Oncogenic Biomarkers – An Overview

3.1 Biomarker Discovery to Clinical Validation

3.2 Specific Technologies Used in Biomarker Discovery

3.2.1 Proteomics

3.2.2 Mass Spectrometry Based Technologies

3.2.3 Principles of Diagnostic Mass Spectrometry

3.2.4 Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS)

3.2.5 Nano LC-MS/MS

3.2.6 MALDI-TOF

3.3 Glycomics

3.4 Metabolomics

3.5 Peptidomics

3.5.1 Enzyme-Linked Immunosorbent Assay (ELISA)

3.6 Selected (Multiple) Reaction Monitoring

3.7 DNA Based Techniques

3.7.1 Microarrays

3.7.2 Small Molecule Real Time (SMRT) DNA Sequencing

3.7.3 Digital PCR

3.7.4 Next Generation Sequencing

3.7.5 Second-Generation Sequencing Platforms

3.7.6 Whole Genome Sequencing

3.7.7 Epigenomics

3.7.8 Bioinformatics and Next Generation Sequencing

3.7.9 Third Generation Sequencing

4.0 Biomarker Validation

4.1 Introduction

4.2 Phases of Biomarker Validation

4.3 Biomarker Validation and Clinical Trials

5.0 Current and Prospective Oncogenic Biomarkers

5.1 Catalogue of Somatic Mutations in Cancer (COSMIC)

5.2 P53 Transcription Factor Oncogenic Mutations

5.2.1 Current Clinical Trials Investigating P53 as an Oncogenic Biomarker

5.3 Epidermal Growth Factor Receptor (EGFR)

5.3.1 EGFR-Activating and Resistance Mutations

5.3.2 Clinically Validated Resistance Mechanisms to EGFR Inhibitors

5.3.3 Current Strategies to Defeat Resistance to EGFR-Mediated Cancer Therapeutics

5.4 BRCA- Mutant Cancers

5.5 PARP-Inhibitors are Making a Comeback

5.5.1 Olaparib – A Pipeline PARP-Inhibitor

5.5.2 Niraparib (MK4827) in Phase III trials

5.5.3 Rucaparib

5.5.4 Veliparib

5.5.5 Novel Biomarkers in the PARP-Inhibitor Response Pathway

5.6 PTEN – Current Leader in Pipeline Onocogenic Biomarkers

5.7 Ataxia Telangiectasia Mutated (ATM) – A Pipeline Target

5.8 TMPRSS2-ERG – A Promising Prostate Cancer Biomarker

5.9 MiR-17/92 Cluster – The Oncomir with Biomarker Potential

5.9.1 Altered MiR-17/92 Expression Correlates with Cancer Pathogenesis

5.9.2 MiR-17/92 Cluster and Colorectal Cancer

5.9.3 MiR-17/92 Cluster and Breast Cancer

5.9.4 MiR-17/92 Cluster and Ovarian Cancer

5.9.5 MiR-17/92 Cluster and Lung Cancer

5.9.6 MiR-17/92 Cluster and Renal Cancer

5.9.7 MiR-17/92 Cluster and Head and Neck Cancer

5.9.8 MiR-17/92 Cluster and Pancreatic Cancer

5.9.9 MiR-17/92 Cluster and Liver Cancer

5.9.10 MiR-17/92 Cluster and Acute Myeloid Leukaemia

5.9.11 MiR-17/92 Cluster and B-Cell Lymphoma

5.9.12 MiR-17/92 Cluster and B-Cell Chronic Lymphocytic Leukemia

5.9.13 Transcriptional Regulators of MiR-17/92 Cluster

5.9.14 Significant Molecular Targets of MiR-17/92

6.0 Cancer Biomarker Test Market Analysis 2013-2018

6.1 Economic Burden of Cancer Worldwide

6.2 Economic Burden of Cancer in the US

6.3 Global Biomarker Test Market Analysis

6.4 Oncology Biomarkers Dominate the Biomarker Market

6.5 Global Cancer Profiling Technology Market

6.6 Global Cancer Biomarker Market Analysis

6.7 Market Share of Oncology Market Within Total Biomarker Market

6.8 US Cancer Biomarker Market

6.9 Oncology Biomarker Market is Fuelled by Year-on-Year Expansion of Research Publications

6.10 Proteomic and Genomic Technologies are Preferred as Methods of Detection by End-Users

7.0 Oncology Biomarker Market Main Industry Players

7.1 23andMe

7.2 Affymetrix

7.3 Ambry Genetics

7.4 Astex Pharmaceuticals

7.5 Atossa Genetics

7.6 CuraGen

7.7 Celera Corporation (Quest Diagnostics)

7.8 Celldex Therapeutics

7.9 deCode Genetics (Amgen)

7.10 Foundation Medicine

7.11 Illumina

7.12 Genelex

7.13 Genomic Health

7.14 Myriad

7.15 Nodality

7.16 OriGene Technologies

7.17 Randox

7.18 Qiagen

8.0 Oncology Biomarker Market Products and Kits

8.1 Oncology Companion Diagnostic Tests

8.1.1 HER2 Tests in Breast Cancer Patients

8.2 23andMe

8.3 Affymetrix

8.4 Ambry Genetics

8.4.1 BRCAPlus

8.4.2 BreastNext

8.4.3 CancerNext

8.4.4 ColoNext

8.4.5 OvaNext

8.4.6 PancNext

8.4.7 RenalNext

8.4.8 Hereditary Diffuse Gastric Cancer Test

8.5 Astex Pharmaceuticals

8.6 Atossa Genetics

8.6.1 Mammary Aspirate Specimen Cytology Test (MASCT™)

8.6.2 ForeCYTE Breast Health Test (SM)

8.6.3 ArgusCYTE Breast Health Test(SM)

8.6.4 FullCYTE Breast Health Test

8.6.5 NextCYTE Breast Health Test

8.7 BioMerieux

8.7.1 THxID™ -BRAF Kit

8.8 Celera (Quest Diagnostics)

8.9 deCode Genetics

8.9.1 deCODE Breast Cancer™

8.9.2 deCODE Prostate Cancer™

8.9.3 deCODE AF™

8.9.4 deCODE Complete™

8.9.5 deCODE Cancer™

8.9.6 deCODE Services

8.10 Foundation Medicine

8.10.1 FoundationOne

8.10.2 FoundationOne Heme

8.11 Illumina

8.11.1 Illumina New-Generation Sequencing Technology

8.11.2 Illumina HiSeq 2500/1500

8.11.3 Illumina HiSeq 2000/1000

8.11.4 Genome Analyzer IIx

8.11.5 Illumina MiSeq

8.11.6 Illumina HiScanHQ

8.11.7 Illumina HiScan and iScan Array

8.12 Genelex

8.13 Genomic Health

8.13.1 Oncotype DX Breast Cancer Test

8.13.2 Oncotype DX Colon Cancer Test

8.13.3 Oncotype DX Prostate Cancer Assay

8.14 Myriad Genetics

8.14.1 BRACAnalysis®

8.14.2 Comprehensive BRACAnalysis®

8.14.3 BRACAnalysis® Rearrangement Test (BART)

8.14.4 Single Site BRACAnalysis®

8.14.5 Multisite 3 BRACAnalysis®

8.14.6 COLARIS®/COLARIS AP®

8.14.7 MELARIS®

8.14.8 PANEXIA®

8.14.9 OnDose®

8.14.10 PREZEON™

8.14.11 THERAGUIDE® 5FU

8.14.12 Prolaris®

8.15 Nodility

8.16 OriGene

8.16.1 TissueScan™ Cancer cDNA Arrays

8.17 Randox

8.17.1 Tumor PSA Marker Array

8.17.2 Tumor Marker Array 3

8.17.3 KRAS/ BRAF/PIK3CA Array

8.18 Qiagen

8.18.1 Genotyping Products

8.18.2 QIAsymphony Platform

8.18.3 Therascreen® EGFR RGQ PCR Kit

8.18.4 Therascreen KRAS RGQ PCR System

8.18.5 Therascreen® IDH1/2 test

8.19 Roche

8.19.1 Cobas® EGFR Mutation Test

9.0 Market Participant Financial and Business Strategy Analysis

9.1 23andMe

9.2 Affymetrix

9.3 Astex Pharmaceuticals (Otuska Pharamceutical)

9.4 Atossa Genetics

9.5 BioMerieux

9.6 Celera (Quest Diagnostics)

9.7 Celldex Therapeutics

9.8 deCode Genetics (Amgen)

9.9 Foundation Medicine

9.10 Illumina

9.11 Genelex

9.12 Genomic Health

9.13 Myriad

9.14 Nodality

9.15 Qiagen

10.0 Objective Business and Strategic Analysis of the Cancer Biomarker Market

10.1 Drivers of Oncogenic Biomarker Market

10.1.1 High demand and Unmet Need Enhances the Global Biomarker Market

10.1.2 Biomarkers are Highly Specific Diagnostic and Prognostic Clinical Tools

10.1.3 Increasing Cancer Prevalence Globally

10.1.4 FDA Support Increases Biomarker Development

10.1.5 More Streamlined Clinical Trials

10.1.6 Significant Growth of High-Impact Oncogenic Biomarker Research

10.1.7 Advancements in Discovery Technologies

10.2 Challenges of the Oncogenic Biomarker Market

10.2.1 Variability of Biomarkers within Different Cancer Subtypes

10.2.2 Integration of Genomics and Biomarker Diagnostics into the Healthcare System

10.2.3 Ethical Considerations

10.3 Restraints of the Cancer Biomarker Market

10.3.1 Initial Investment into Biomarker Discovery and Development

10.3.2 Are Biomarkers Profitable for Smaller Companies?

10.4 Opportunities for the Cancer Biomarker Market

10.4.1 Personalized Medicine Market Opportunities

10.4.2 Companion Diagnostics

List of Figures

Figure 2.1: Global Cancer Statistics – Key Facts

Figure 2.2: Number of Lung, Breast and Colorectal Cancer Diagnoses Globally, 2012

Figure 2.3: Percentage of Lung, Breast and Colorectal Cancer Diagnoses Globally, 2012

Figure 2.4: Number of Lung, Liver and Stomach Cancer Deaths Globally, 2012

Figure 2.5: Percentage of Lung, Liver and Stomach Cancer Deaths Globally, 2012

Figure 2.6: Global Cancer Incidence, Men 2012 (per 100,000)

Figure 2.7: Global Cancer Mortality, Men 2012 (per 100,000)

Figure 2.8: Global Cancer Incidence, Women 2012 (per 100,000)

Figure 2.9: Global Cancer Mortality, Women 2012 (per 100,000)

Figure 2.10: Number (Millions) of Smokers (Men and Women) in China, Russia, India, the UK and USA

Figure 2.11: Incidence and Mortality Rates of Global Lung Cancer (Male and Female)

Figure 2.12: Incidence and Mortality Rates of Global Colorectal Cancer (Male and Female)

Figure 2.13: Incidence and Mortality Rates of Global Prostate Cancer

Figure 2.14: Global Incidence and Mortality of All Cancer Types (excl non-melanoma skin-cancer) per 100,000, Male and Female

Figure 2.15: Combined Global Prostate, Breast, Colorectal, Lung and Bladder Cancer Incidence and Mortality by Male and Female

Figure 2.16: Cancer Deaths in Women, Globally according to Cancer Type

Figure 2.17: Estimated Age-Standardised Incidence Rate per 100,000 of Breast Cancer Globally

Figure 2.18: Top Three Cancers Leading to Global Economic Burden of Cancer ($ Billion)

Figure 2.19: Top 20 Cancers in the USA, Adults (Male and Female)

Figure 2.20: Top Adult Male Cancers, USA, Estimated Five Year Prevalence 2012-2017

Figure 2.21: Top Adult Female Cancers, USA, Estimated Five Year Prevalence 2012-2017

Figure 2.22: US Age Adjusted Cancer Death Rates Per 100,000 (Male) by Cancer Type, 1930-2009

Figure 2.23: US Age Adjusted Cancer Death Rates Per 100,000 (Female) by Cancer Type, 1930-2009

Figure 2.24: Incidence and Mortality of Lung Cancer (Male) Patients in the Americas

Figure 2.25: Incidence and Mortality of Lung Cancer (Female) Patients in the Americas

Figure 2.26: Incidence and Mortality of Colorectal Cancer (Male and Female) Patients in the Americas

Figure 2.27: Colorectal Cancer Incidence Rates (per 100,000) by Race/Ethnicity and Sex, USA

Figure 2.28: Colorectal Cancer Death Rates (per 100,000) by Race/Ethnicity and Sex, USA

Figure 2.29: Colorectal Cancer Incidence Rates (per 100,000) by State, USA

Figure 2.30: Colorectal Cancer Mortality Rates (per 100,000) by State, USA

Figure 2.31: Adults Aged 50–75 Years (%) That are Up-to-Date with Colorectal Test Screening, by State, United States

Figure 2.32: Incidence and Mortality of Prostate Cancer (Male) Patients in the Americas

Figure 2.33: Incidence and Mortality of Melanoma (Male and Female) Patients in the Americas

Figure 3.1: Integration of Oncogenic Biomarker Data to Cancer Diagnosis and Clinical Decisions

Figure 3.2: Influence of Biomarker Market on R&D, Molecular Diagnostics, Emerging Diagnostics and Independent Clinical Molecular Diagnostic Services

Figure 3.3: Biomarker Discovery to Clinical Assay Development and Validation Process

Figure 3.4: Mass Spectrometry Based Technologies in Oncogenic Biomarker Discovery

Figure 3.5: Principles of Enzyme-Linked Immunosorbant Assay (ELISA)

Figure 4.1: The Different Phases of Fit-For-Purpose Biomarker Validation

Figure 4.2: Biomarker Validation Using ELISA Technique

Figure 5.1: Frequency of Genetic Mutation by Cancer Subtype

Figure 5.2: Oncogenic Biomarker P53 Signalling Pathway: Activators, Effectors, Inhibitors and Cellular Outcomes

Figure 5.3: P53 Somatic Mutation Prevalence by Tumor Site

Figure 5.4: P53 Germline Mutation Prevalence by Tumor Site

Figure 5.5: EGFR Signalling Pathways and Potential Biomarker Proteins

Figure 5.6: Clinically Validated Resistance Mechanisms to EGFR Inhibitors

Figure 5.7: BRCA Mutation Increases the Risk of Breast and Ovarian Cancer

Figure 5.8: Proactive Cancer Management and Preventative Measures Reduces the Risks of Developing BRCA-associated Breast and Ovarian Cancer

Figure 6.1: Economic Burden of Cancer in the US, Direct and Indirect Costs ($ billion)

Figure 6.2: Economic Burden of Cancer in the US, Direct and Indirect Costs (%)

Figure 6.3: Global Biomarker Market Worth (Billions) and CAGR (%) 2011-2018

Figure 6.4: Oncogenic Biomarker Share of Total Personalized Medicine Biomarker Space

Figure 6.5: Oncogenic Biomarker Market Distribution by Cancer Type

Figure 6.6: Global Cancer Profiling Technology Market Worth (Billions) and CAGR 2013-2018

Figure 6.7: Global Cancer Biomarker Market Worth (Billions) and CAGR (%) 2009-2018

Figure 6.8: Global Oncology Biomarker Market as a Percentage of Total Biomarker Market 2013-2018

Figure 6.9: USA Cancer Biomarker Market Share Compared to Global Biomarker Market 2013-2018

Figure 6.10: Number of Peer-Reviewed Publications in the Area of Oncology Biomarker Research 2008-2013

Figure 6.11: Number of Peer-Reviewed Publications ion Oncogenes within Oncogenic Biomarker Research 2008-2013

Figure 6.12: Number of Peer-Reviewed Publications on MicroRNAs Within Oncology Biomarker Research 2008-2013

Figure 6.13: Number of Peer-Reviewed Publications on Epigenetic Modifications Within Oncology Biomarker Research 2008-2013

Figure 6.14: Number of Peer-Reviewed Publications by the National Cancer Institute Within Oncology Biomarker Research 2008-2013

Figure 6.15: Number of Peer-Reviewed Publications on Tumor Suppressor Genes Within Oncology Biomarker Research 2008-2013

Figure 6.16: Number of Peer-Reviewed Publications on incRNA Within Oncology Biomarker Research 2008-2013

Figure 6.17: Most Popular Proteomic and Genomic Technologies Performed by End-Users

Figure 7.1: Celldex Therapeutics Product Pipeline

Figure 7.2: Single Cell Network Profiling (SCNP) Technology by Nodality

Figure 7.3: Developed Functional Assays that Nodality has explored using new SCNP Technology

Figure 8.1: HER2 Testing Algorithm for Breast Cancer

Figure 8.2: HER2 Cellular Signalling

Figure 8.3: QUICKFACTS: Herceptin – Mechanism of Action

Figure 8.4: Illumina New Generation Sequencing Technology Workflow Station

Figure 8.5: Genomic Health Studies Used in the Development of the DCIS Score Algorithm

Figure 8.6: Genomic Health Gene Panel Used for Oncotype DX Breast Cancer Test

Figure 8.7: Genomic Health Gene Panel Used for Oncotype DX Colon Cancer Test

Figure 8.8: Genomic Health Oncotype DX Prostate Cancer Test Development Process

Figure 8.9: Genomic Health Gene Panel Used for Oncotype DX Prostate Cancer Test

Figure 8.10: OriGene's TissueScan Cancer cDNA Array Sequence of Analysis

Figure 9.1: Private Funding Gained by 23andMe 2007-2012

Figure 9.2: Affymetrix Revenue by Business Segment (Percentage), 2013

Figure 9.3: Affymetrix Revenue by Business Segment (Percentage), 2013

Figure 9.4: Affymetrix Total Revenue 2007-2013

Figure 9.5: Affymetrix Revenue by Product Division – Consumables, Instruments 2010-2012

Figure 9.6: Affymetrix Core Product Sales – Gene Expression, Genetic Analysis & Clinical Applications and Life Science Reagents, 2011-2012

Figure 9.7: Affymetrix Revenue Derived from Outside the US, 2009-2012

Figure 9.8: Affymetrix Revenue Derived from the US, 2009-2012

Figure 9.9: Affymetrix Net Loss, 2009-2012

Figure 9.10: Affymetrix Research and Development Funding, 2009-2012

Figure 9.11: Affymetrix Revenue Generated within USA (Percentage) 2010-2012

Figure 9.12: Astex Pharmaceuticals Priority Pipeline Products SGI-110 and AT13387 by Indication, Clinical Phase and Timeline

Figure 9.13: Astex Pharmaceuticals Revenue Generated 2008-2012

Figure 9.14: Astex Pharmaceuticals Net Income 2009-2012

Figure 9.15: Atossa Genetics Total Revenue (US$) 2011, 2012

Figure 9.16: Atossa Genetics Revenue (US$) Generated by MASCT Sales and ForeCYTE & ArgusCYTE Diagnostic Testing, 2012

Figure 9.17: Atossa Genetics Percentage Revenue Generated by MASCT Sales and ForeCYTE & ArgusCYTE Diagnostic Testing, 2012

Figure 9.18: Quest Diagnostics Revenue ($ Billions) 2008-2013

Figure 9.19: Quest Diagnostics Operating Revenue ($ Billions) 2008-2013

Figure 9.20: Quest Diagnostics Net Income ($ Billions) 2008-2013

Figure 9.21: Celera (Quest Diagnostics) Historic Revenue Generated 2008-2010

Figure 9.22: Celera (Quest Diagnostics) Historic Gross Margin Generated 2008-2010

Figure 9.23: Celera (Quest Diagnostics) Historic Revenue Generated– Laboratory Services and
Products 2008-2010

Figure 9.24: Celera (Quest Diagnostics) Historic Revenue (%) Generated by Distribution Agreement with Abbott 2008-2010

Figure 9.25: Celera (Quest Diagnostics) Historic Research and Development Spending 2008-2010

Figure 9.26: deCode Genetics Historic Net Loss Incurred 2004-2008

Figure 9.27: Foundation Medicine International Sales – FoundationOne 2012-2013

Figure 9.28: Foundation Medicine International Revenue 2012-2013

Figure 9.29: Foundation Medicine Geographical (USA) Revenue Percentage 2011-2013

Figure 9.30: Illumina Revenue Generated ($ Billions) 2010-2013

Figure 9.31: Illumina Net Income Generated ($ Billions) 2010-2013

Figure 9.32: Genomic Health Oncotype DX Test Revenue 2008-2013

Figure 9.33: Myriad Revenue Generated 2007-2014

Figure 9.34: Operating Income Generated by Myriad 2007-2013

Figure 9.35: Myriad Revenue Generated by Molecular Diagnostic Testing and Companion Diagnostic Services, 2012-2013

Figure 9.36: Future Molecular Diagnostic Pipeline of Myriad

Figure 9.37: Customer Profile of Qiagen – Percentage of Net Sales 2012/2013

Figure 9.38: Qiagen Global Net Sales 2007-2013

Figure 9.39: Qiagen Operating Income 2007-2013

Figure 9.40: Qiagen Global Net Income 2007-2013

List of Tables

Table 2.1: QUICKFACTs- Top Five Most Frequent Cancers in Men and Women, Globally

Table 2.2: Main Clinical Stages of Lung Cancer

Table 2.3: Current Therapeutic Options for Lung Cancer

Table 2.4: QUICKFACTs- Estimated Age-Standardised Incidence Rate per 100,000 of Breast Cancer per Country, Worldwide

Table 2.5: Risk Factors of Colorectal Cancer

Table 3.1: Important Advantages of Using Biomarkers as Diagnostic Tools

Table 3.2: Biomarkers in Early Drug Development and Decision Making

Table 3.3: Biomarkers in Later Drug Development and Decision Making

Table 3.4: Functions of Biomarkers within the Healthcare Setting

Table 3.5: Ideal Attributes of Clinical Oncogenic Biomarkers

Table 3.6: Main Technologies Used in the Discovery of Biomarkers

Table 3.7: Proteomic Technologies Used in Biomarker Discovery

Table 3.8: Types of Cancer Aided Diagnostically by Mass Spectrometry

Table 3.9: Recommendations for Use of MALDI-TOF MS in Cancer Diagnostics

Table 3.10: Metabolomic Discovered Potential Oncogenic Biomarkers

Table 3.11: Cancer Biomarkers in Clinical Practice Using ELISA Technology

Table 3.12: Putative Cancer Biomarkers that can be Detected using ELISA Technology

Table 3.13: Advantages of Selected (Multiple) Reaction Monitoring Technique in Biomarker Discovery

Table 3.14: Major Advantages of Microarray Assays

Table 3.15: Applications of Microarrays

Table 3.16: Applications of Microarray Technology in Cancer Diagnostics

Table 3.17: Commercially Available Microarray Kits for Cancer Diagnostics

Table 3.18: Recommendations for Use of Microarrays in Cancer Diagnostics

Table 3.19: Digital PCR in Comparison to Real-time PCR and Traditional PCR

Table 3.20: Advantages of Digital PCR

Table 3.21: Applications of Digital PCR

Table 4.1: Current General Classes of Biomarker Assay as Defined by the American Association of Pharmaceutical Scientists

Table 4.2: Comparison of Validative Properties of Different Bioassay Classes

Table 5.1: Catalogue of Somatic Mutations in Cancer (COSMIC) Current Statistics

Table 5.2: Important Genetic Oncogenic Biomarkers and Their Application in Treatment

Table 5.3: P53 Somatic Mutation Prevalence by Tumor Site

Table 5.4: P53 Germline Mutation Prevalence by Tumor Site

Table 5.5: List of P53 Down-regulated Gene Targets

Table 5.6: List of P53 Up-regulated Gene Targets

Table 5.7: Positive Regulators of Epidermal Growth Factor Receptor (EGFR) Activity

Table 5.8: Types of Cancer Associated with EGFR Over-expression

Table 5.9: EGFR-Activating and Resistance Mutations Identified in Lung Adenocarcinoma

Table 5.10: Current Next Generation EGFR Inhibitors that Target the T790M Mutation

Table 5.11: Prevalence of Deleterious Mutations in BRCA1 and BRCA2 Genes

Table 5.12: Prevalence of Deleterious Mutations in BRCA1 and BRCA2 in Individuals of Ashkenazi Ancestry

Table 5.13: Risk Factors for Hereditary Breast and Ovarian Cancer (HBOC)

Table 5.14: PARP Inhibitors in Late-Stage Development

Table 5.15: Novel and Potential Biomarkers Within the PARP-Inhibitor Response Pathway

Table 5.16: Negative Regulators of PTEN Protein Expression

Table 5.17: Positive Regulators of PTEN Protein Expression

Table 5.18: ATM Molecular Targets and Protein Interactions

Table 5.19: Key Facts Regarding MiR-17/92 Cluster

Table 5.20: Expression Levels of Individual MiR-17/92 Biomarkers in Cancer, Cardiovascular Disease, Alzheimer's, Multiple Sclerosis, Aging and Normal Development

Table 5.21: Functional and Validated Positive Regulators of MiR-17/92

Table 5.22: Functional and Validated Negative Regulators of MiR-17/92

Table 5.23: Potential Regulators of MiR-17/92

Table 5.24: Cellular Signal Transduction Pathways Regulated by the MiR-17/92 Cluster

Table 5.25: Specific Cell Death Protein Targets of the MiR-17/92 Cluster

Table 5.26: Specific Cell Cycle Arrest Protein Targets of the MiR-17/92 Cluster

Table 5.27: Specific Cell Cycle Regulation Protein Targets of the MiR-17/92 Cluster

Table 5.28: Specific Heart and Lung Development Protein Targets of the MiR-17/92 Cluster

Table 5.29: Specific Cell Proliferation Protein Targets of the MiR-17/92 Cluster

Table 6.1: Global Biomarker Market Worth (Billions) and CAGR (%) 2011-2018

Table 6.2: Main Diagnostic Areas Within Oncology Biomarker Market

Table 6.3: Future Diagnostic Areas With High Potential Within Oncology Biomarker Market

Table 6.4: Global Cancer Profiling Technology Market Worth (Billions) and CAGR 2013-2018

Table 6.5: Global Cancer Biomarker Market Worth (Billions) and CAGR (%) 2009-2018

Table 6.6: USA Cancer Biomarker Market Share Compared to Global Biomarker Market 2013-2018

Table 6.7: Main Sub-Sets of Oncogenic Biomarker Research Published 2008-2013

Table 7.1: Patent Listing of Affymetrix Array technology

Table 7.2: Patent Listing of Affymetrix Genotyping Technology

Table 7.3: Patent Listing of Affymetrix Expression and Profiling Technology

Table 7.4: Advantages of Astex Pharmaceuticals Pyramid™ Fragment-Drug-Discovery System

Table 7.5: Astex Pharmaceuticals Pipeline Portfolio

Table 7.6: Astex Pharmaceuticals Pipeline Portfolio Funded Completely by Partner Companies

Table 7.7: Potential Business Partnerships of Celldex Therapeutics

Table 7.8: Illumina Core Technologies

Table 7.9: Illumina Core Technology Applications

Table 7.10: Illumina Instrument Product Portfolio

Table 7.11: Illumina Assay Product Portfolio

Table 7.12: Genetic Test Panel Available from Genelex for Research Institutions and Clinical Trials

Table 7.13: Pre-Clinical, Clinical and Commercial Applications of SCNP by Nodality

Table 7.14: Qiagen Timeline of Events, 1994-2012

Table 7.15: QUICKFACTs - Range of Product Groups from Qiagen

Table 8.1: Types of Diagnostic Tests Available to Determine HER2 Status in Breast Cancer Patients

Table 8.2: Validated HER2 Tests for Cancer

Table 8.3: Advantages and Limitations of IHC HER2 testing applied to breast cancer

Table 8.4: In-Situ Hybridization Determination of HER2 Expression by PathVysion® and HER2 FISH pharmDxTM

Table 8.5: HER2 CISH Determination

Table 8.7: Validated FISH Kits for HER2 Testing in Breast Cancer

Table 8.8: Validated SISH Kits for HER2 Testing in Breast Cancer

Table 8.9: Validated CISH Kits for HER2 Testing in Breast Cancer

Table 8.10: Advantages and Limitations of ISH Techniques Applied to HER2 Testing in Breast Cancer

Table 8.11: 23andMe Disease Risk Genetic Test Panel

Table 8.12: 23andMe Carrier Status Genetic Test Panel

Table 8.13: 23andMe Drug Response Genetic Marker Test Panel

Table 8.14: 23andMe Genetic Traits Test Panel

Table 8.15: QUICKFACTs - Product Overview of Affymetrix

Table 8.16: Microarray Products by Affymetrix

Table 8.17: Affymetrix Research Services Laboratory (ARSL) Premier Services

Table 8.18: Genetic Applications of Axiom® Technology by Affymetrix

Table 8.19: Clinical Diagnostic Test Kits Available from Ambry Genetics

Table 8.20: Ambry Genetics Cancer Test Portfolio and Genetic Biomarkers

Table 8.21: Ambry Genetics Comprehensive List of Genetic Tests by Disease and Genetic Biomarkers

Table 8.22: Ambry Genetics BRCA1/2 Breast Cancer Test Portfolio

Table 8.23: Ambry Genetics Genome Sequencing Services

Table 8.24: Ambry Genetics New Generation Sequencing Platform Portfolio & Applications

Table 8.25: Range of Small Molecule Therapeutics Available from Astex Pharmaceuticals

Table 8.26: Genetic Tests Available from BHL/Celera

Table 8.27: Panel of BHL Clinical Diagnostic Tests

Table 8.28: Genetic Diagnostic Tests Available from deCode Genetics

Table 8.29: Disease States that are Included in the deCODE Complete™ Genetic Screen

Table 8.30: Panel of Diseases Screened for in the deCODE Cancer™ Test

Table 8.31: deCODE Genetics Genotyping and Sequencing Service

Table 8.32: deCODE Genetics Data Management, Protection and Storage Service

Table 8.33: deCODE Genetics Sequence Inputation and Data Analysis Service

Table 8.34: FoundationOne Assay Technical Specifications

Table 8.35: FoundationOne Assay Oncogenic Gene Portfolio

Table 8.36: FoundationOne Heme Assay Oncogenic Gene Portfolio

Table 8.37: Illumina HiSeq 2500/1500 Performance Parameters

Table 8.38: Illumina HiSeq 2000/1000 Performance Parameters

Table 8.39: Genome Analyzer IIx Performance Parameters

Table 8.40: Illumina MiSeq Product Specifications

Table 8.41: Illumina HiScanHQ Product Specifications

Table 8.42: Illumina HiScan and iScan Array Product Applications

Table 8.43: Illumina HiScan and iScan Array Kits

Table 8.44: Predictive Genetic Tests Available from Myriad

Table 8.45: Services offered with BRACAnalysis® Testing from Myriad

Table 8.46: Advantages of BRACAnalysis® Testing

Table 8.47: QUICK FACTs- Prevalence of Deleterious Mutations in BRCA1 & BRCA2 Genes

Table 8.48: QUICK FACTs- prevalence of deleterious mutations in BRCA1 and BRCA2 in individuals of Ashkenazi Ancestry

Table 8.49: QUICK FACTs- Risk Factors for Hereditary Breast and Ovarian Cancer (HBOC)

Table 8.50: QUICKFACTs- BRACAnalysis® Panel of Assays

Table 8.51: COLARIS® Test Range by Myriad

Table 8.52: COLARIS AP® Test Range by Myriad

Table 8.53: MELARIS® Test Range from Myriad

Table 8.54 Personalized Medicine Tests from Myriad

Table 8.55: The Prolaris Score for Prostate Cancer

Table 8.56: OnDose® Testing Procedure from Myriad

Table 8.57: OriGene TissueScan cDNA Array Oncology Product Portfolio

Table 8.58: Qiagen Genotyping Products for Sample Collection, stabilization and Storage

Table 8.59: Qiagen Genotyping Products for Genomic DNA Isolation and Purification

Table 8.60: Qiagen Genotyping Products for PCR Based Genotyping Analysis

Table 8.61: Qiagen Products for Genotyping Analysis

Table 8.62: Qiagen Genotyping Products for PCR Detection

Table 8.63: Qiagen Assays for Genetic Analysis

Table 8.64: Qiagen Pyrosequencing-Based Genetic Analysis Products

Table 8.65: Specifications and Features of Qiagen's QIAsymphony and QIAsymphony RGQ

Table 9.1: Drug Classes Investigated by 23andMe Using Genome Wide Association Studies

Table 9.2: Acquisition Profile of Affymetrix

Table 9.3: Genetic Applications of Axiom® Technology by Affymetrix

Table 9.4: Diversified Business Units of Affymetrix

Table 9.5: Affymetrix AgBio Microarray Portfolio

Table 9.6: BioMerieux Immunodiagnostic Product Portfolio

Table 9.7: BioMerieux Microbiology Product Portfolio

Table 9.8: BioMerieux Molecular Diagnostic Product Portfolio

Table 9.9: Celera (Quest Diagnostics) Historic Operating (Loss) (US$) – Laboratory Services and Products 2008-2010

Table 9.10: Diagnostic Test Product Categories Manufactured by BHL/Celera and Exclusively Distributed by Abbott

Table 9.11: Celldex Therapeutics R&D Expenses ($) 2010-2012

Table 9.12: Price Listing of Genelex Familial Genetic Tests

Table 9.13: Myriad - Core Business Decisions and Impact on Industry

Table 9.14: Future Test Portfolio of Myriad

Table 9.15: Nodality's Single Cell Network Profiling (SCNP) Technology as a Systems Based Biology Approach to Drug Discovery and Validation

Table 10.1: Drivers of the Oncogenic Biomarker Market

Table 10.2: Integration of Genomics and Biomarker Diagnostics into the Healthcare System

Table 10.3: Challenges of the Cancer Biomarker Market
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4

FEATURED COMPANIES

  • 23andMe
  • Astex Pharmaceuticals
  • Celldex Therapeutics
  • Foundation Medicine
  • Illumina
  • OriGene Technologies
  • MORE
“GLOBAL & USA CANCER BIOMARKER MARKET to 2018 (Identification, Technologies, Market Analysis, Competitor Profiles, Companion Diagnostic Co-development, Business Strategies, Industry Trends, and Pipeline Analysis)” is a comprehensive report on the cancer biomarker industry and its impact on the health system. This report tackles the growing market interest in oncogenic biomarkers, personalized medicine, companion diagnostics and the associated market environment.

Cancer biomarkers are molecular or genetic moieties (e.g., cells, proteins/peptides, genetic mutations, gene products, enzymes, or hormones) that not only are readily identifiable, but easily quantified in the lab setting. They function primarily to identify or correlate significantly with the severity or occurrence of a certain disease state. The rise in number of oncogenic biomarkers over the last number of years has massive potential in the healthcare industry and serves to propel both the personalized medicine and companion diagnostic markets.

One of the most import aspects of biomarkers is their use to diagnose and assess the progress of disease states in patients. As quantitative markers, these agents also offer the ability to monitor response to certain drug treatments and so are important in the area of personalized medicine.

Individualized, targeted or personalized medicine aims to increase the efficacy of therapeutics via genetic testing and companion diagnostics. Personalized therapeutics and associated companion diagnostics will be more specific and effective thereby giving pharma/biotech companies a significant advantage to recuperate R&D costs. Personalized medicine will reduce the frequency of adverse drug reactions and therefore have a dramatic impact on health economics. Developmental and diagnostic companies will benefit from lower discovery and commercialization costs and more specific market subtypes.

This report describes the current technologies that are propelling the cancer biomarker and companion diagnostic market. It examines the current genetic diagnostic tests and companion diagnostic assays that are in use by the medical and pharmaceutical industry today. Current developments in personalized medicine and the pharmacogenomics revolution are discussed. The emerging trends that appear in the global market and the most developed market (US) are elucidated and analysed. This study reveals market figures of the overall biomarker market and the cancer biomarker space (2013-2018). Forecast projections and future growth rates are provided to give the reader a forthcoming perspective of this growing industry.

The study also provides a comprehensive financial, business strategy and product review of key players in the cancer biomarker industry. Strategic drivers and restraints of this market are revealed and market opportunities and challenges are identified.

In summary, the cancer biomarker and associated companion diagnostic market have huge opportunities for growth. This industry will revolutionize the healthcare system and will improve therapeutic effectiveness and reduce the severity of adverse effects. It has enormous potential for investment and the emergence of genetic-based in vitro diagnostics.
Note: Product cover images may vary from those shown
5 of 4
- 23andMe
- Affymetrix
- Ambry Genetics
- Astex Pharmaceuticals
- Atossa Genetics
- BioMerieux
- CuraGen
- Celera Corporation (Quest Diagnostics)
- Celldex Therapeutics
- deCode Genetics (Amgen)
- Foundation Medicine
- Illumina
- Genelex
- Genomic Health
- Myriad
- Nodality
- OriGene Technologies
- Randox
- Qiagen
Note: Product cover images may vary from those shown
Adroll
adroll